Literature DB >> 22935770

Applicability of a keratinocyte gene signature to predict skin sensitizing potential.

Jochem W van der Veen1, Tessa E Pronk, Henk van Loveren, Janine Ezendam.   

Abstract

There is a need to replace animal tests for the identification of skin sensitizers and currently many alternative assays are being developed that have very promising results. In this study a gene signature capable of very accurate identification of sensitizers was established in the HaCaT human keratinocyte cell line. This signature was evaluated in a separate study using six chemicals that are either local lymph node (LLNA) false-positive or false-negative chemicals in addition to nine sensitizers and four non-sensitizers. Similar studies do not apply these more difficult to classify chemicals, which show the true potential for human predictions of an assay. Although the gene signature has improved prediction accuracy compared to the LLNA, the misclassified compounds were comparable between the two assays. Gene profiling also showed a sensitizer specific response of the Nrf2-keap1 and Toll-like receptor signaling pathways. After exposure to non-sensitizing chemicals that induce either of the pathways the signature misclassified all Nrf2-inducers, while the Toll-like receptor ligands were correctly classified. In conclusion, we confirm that keratinocyte based prediction assays may provide essential information on the properties of compounds. Furthermore, chemical selection is critical for assessment of the performance of in vitro alternative assays.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935770     DOI: 10.1016/j.tiv.2012.08.023

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  1 in total

1.  Biomarkers for circadian rhythm disruption independent of time of day.

Authors:  Kirsten C G Van Dycke; Jeroen L A Pennings; Conny T M van Oostrom; Linda W M van Kerkhof; Harry van Steeg; Gijsbertus T J van der Horst; Wendy Rodenburg
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.